Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesRecurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Childhood Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- Drug: HDAC inhibitor AR-42Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 13
- Registration Number
- NCT01798901
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia FollowingAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Acute Myeloid LeukemiaMyelodysplastic SyndromeAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 34
- Registration Number
- NCT01174888
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Phase 2
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: lintuzumab
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Alison Walker
- Target Recruit Count
- 7
- Registration Number
- NCT00997243
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
News
No news found